Achillion Provides Update on Clinical HCV Development Programs

[at noodls] – – Drug-Drug Interaction Study of Sovaprevir and ACH-3102 Completed – – ACH-2684, Second-Generation Protease-Inhibitor, Achieves Comparable Activity in Cirrhotic Versus Non-Cirrhotic Patients – – Posters … more

View todays social media effects on ACHN

View the latest stocks trending across Twitter. Click to view dashboard